This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content



AboutAboutTherapy Area OverviewRisk Factors of Ulcerative ColitisDiagnosingDiagnosingSigns and SymptomsComorbidities & PathophysiologyTreatmentTreatment guidelinesPfizer Treatment OptionsDisease NavigatorDisease NavigatorDisease NavigatorTreatmentTreatment guidelinesPfizer Treatment Options

Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information. Adverse event reporting can be found at the bottom of the page.

The Purpose & Intention of Treating Ulcerative Colitis

In the past decade there have been major advances in investigations, pharmacological, non-pharmacological and surgical interventions for patients with IBD. This has allowed patients' treatment  regime to be personalized to include medication, lifestyle changes, and possibly surgery.


The goal is to minimize the impact of UC on a patient's daily life, prevent disease progression, and enhance overall well-being. Collaborating closely with healthcare providers and following a comprehensive treatment approach can greatly support patients in effectively managing UC and achieving the best possible outcomes.

Treatment Guidelines for UC
To learn about guidelines for specific treatments then please click on the drop downs below.

BSG Guidelines1

Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients.

This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dieticians (British Dietetic Association), Radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn’s and Colitis UK). A systematic review of 88247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence and expert opinion-based recommendations for pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn’s disease.1

View the full guidance here.


NICE Guidelines2

This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

NICE has also produced a guideline on colonoscopic surveillance for adults with ulcerative colitis, Crohn's disease or adenomas.


This guideline includes new recommendations on inducing remission in mild-to-moderate ulcerative colitis. These supplement the existing recommendations on:

Who is it for?

  • Healthcare professionals
  • Commissioners and providers
  • People with ulcerative colitis and their families and carers

View the full guidance here

Stride Guidelines3

This guideline contains updated treatment targets for IBD were developed during the Selecting Therapeutic Targets in Inflammatory Bowel Disease II (STRIDE-II) initiative in 2021. The aim was to provide contemporary consensus recommendations for use in clinical practice.

Consensus recommendations were drafted and modified based on a systematic literature review and iterative surveys of 89 IOIBD members Consensus was reached if > 75% of participants scored a recommendation between 7 and 10 on a 10-point rating scale (1, do not agree at all; 10, agree completely).

View Complete STRIDE Guidelines Here

H3 (Mobile)Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults Gut 2019;68:s1-s106.

Overview: Ulcerative colitis: Management: Guidance (no date) NICE. Available at: (Accessed: 25 May 2023).

Turner, Dan et al. “STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.” Gastroenterology vol. 160,5 (2021): 1570-1583. doi:10.1053/j.gastro.2020.12.031
Learning Academy
Inflammation Disease Navigator

Click below to view the Immuno-navigator tool. An interactive tool to help you manage discussions with your patients . 

Visit the Navigator Tool
Patient Support Materials (pdf)
PP-IFA-GBR-0638 July 2023

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2023 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021